Aprea Therapeutics, Inc. - Common Stock (APRE)
Frequently Asked Questions About Aprea Therapeutics, Inc. - Common Stock (APRE)
Does Aprea Therapeutics have a pipeline of products?
Yes, Aprea has a pipeline of product candidates at various stages of development, focusing on therapeutic options for patients with cancers driven by p53 mutations or deficiencies.
Has Aprea Therapeutics engaged in any collaborations?
Yes, Aprea has formed various collaborations with academic institutions and other biopharmaceutical companies to enhance its research and development capabilities.
How can investors stay updated on Aprea's progress?
Investors can stay updated on Aprea's progress by following company announcements, press releases, the investor relations section of its website, and financial news related to the biotechnology sector.
How does Aprea plan to market its therapies?
Aprea plans to market its therapies by establishing partnerships with healthcare providers, engaging in direct-to-consumer strategies, and working with oncology stakeholders to increase awareness.
How does Aprea Therapeutics approach drug discovery?
Aprea employs a science-driven approach for drug discovery, focusing on exploiting the unique vulnerabilities of cancer cells by targeting the p53 pathway with innovative therapies.
How is Aprea funded?
Aprea Therapeutics is funded through a combination of public investment, venture capital financing, and government grants aimed at supporting innovative biotechnology research.
Is Aprea Therapeutics publicly traded?
Yes, Aprea Therapeutics, Inc. is publicly traded on the Nasdaq stock exchange under the ticker symbol 'APRE'.
What are Aprea's lead product candidates?
Aprea's lead product candidates include aprataxin (APG-115), an investigational drug targeting cancers with mutant p53, and other compounds aimed at reactivating wild-type p53 function.
What are the key milestones for Aprea Therapeutics?
Key milestones for Aprea include advancing its drug candidates through various phases of clinical trials, obtaining regulatory approvals, and commercializing its therapies.
What are the potential side effects of Aprea's drug candidates?
As with any investigational therapies, potential side effects may vary, but they are rigorously assessed in clinical trials to establish safety profiles before the drugs can be marketed.
What does Aprea Therapeutics do?
Aprea Therapeutics, Inc. is a biotechnology company focused on developing novel cancer therapeutics that target the mutational landscape of cancer cells. Their primary focus is on developing drugs that target the p53 tumor suppressor pathway.
What is Aprea’s mission?
Aprea’s mission is to develop transformative therapies for patients with cancer, particularly those ailments driven by p53 mutations, to improve survival rates and quality of life.
What is the competitive landscape for Aprea Therapeutics?
The competitive landscape for Aprea includes other biotechnology companies and pharmaceutical firms focusing on oncology treatments, particularly those targeting p53 alterations in cancers.
What is the patent strategy of Aprea Therapeutics?
Aprea Therapeutics employs a robust patent strategy to protect its innovative drug candidates and methodologies, ensuring exclusivity in the market for its unique therapies.
What is the significance of the p53 protein in cancer treatment?
The p53 protein is known as the ‘guardian of the genome’ as it plays a crucial role in regulating the cell cycle, helping prevent cancer formation. Mutated p53 genes are common in various cancer types, making it a prime target for therapeutic interventions.
What is the stage of Aprea’s clinical trials?
Aprea Therapeutics is involved in multiple phases of clinical trials as it evaluates the safety and efficacy of its investigational therapies in patients with specific cancer types.
What is the strategic vision of Aprea Therapeutics?
Aprea’s strategic vision revolves around establishing itself as a leader in cancer therapeutics by focusing on the p53 pathway and developing innovative treatments that address unmet medical needs.
When was Aprea Therapeutics founded?
Aprea Therapeutics was founded in 2010, drawing on extensive research into the p53 protein and its role in cancer biology to inform the development of its therapies.
Where is Aprea Therapeutics headquartered?
Aprea Therapeutics is headquartered in Boston, Massachusetts, a hub for biotechnology and innovative healthcare initiatives.
Who are Aprea's key executives?
Aprea Therapeutics' key executives include the CEO, the Chief Scientific Officer, and other senior leaders working together to advance their research and operational strategies.
What is the current price of Aprea Therapeutics, Inc. - Common Stock?
The current price of Aprea Therapeutics, Inc. - Common Stock is 1.780
When was Aprea Therapeutics, Inc. - Common Stock last traded?
The last trade of Aprea Therapeutics, Inc. - Common Stock was at 2:44 pm EDT on April 4th, 2025
What is the market capitalization of Aprea Therapeutics, Inc. - Common Stock?
The market capitalization of Aprea Therapeutics, Inc. - Common Stock is 9.76M
How many shares of Aprea Therapeutics, Inc. - Common Stock are outstanding?
Aprea Therapeutics, Inc. - Common Stock has 5.48M shares outstanding.